Inactivation of SARS-CoV-2 in All Blood Components Using Amotosalen/Ultraviolet A Light and Amustaline/Glutathione Pathogen Reduction Technologies
No cases of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transfusion-transmitted infections (TTI) have been reported. The detection of viral RNA in peripheral blood from infected patients and blood components from infected asymptomatic blood donors is, however, concerning. This study...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-04-01
|
| Series: | Pathogens |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-0817/11/5/521 |
| _version_ | 1797497063979614208 |
|---|---|
| author | Felicia Santa Maria Yan-Jang S. Huang Dana L. Vanlandingham Peter Bringmann |
| author_facet | Felicia Santa Maria Yan-Jang S. Huang Dana L. Vanlandingham Peter Bringmann |
| author_sort | Felicia Santa Maria |
| collection | DOAJ |
| description | No cases of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transfusion-transmitted infections (TTI) have been reported. The detection of viral RNA in peripheral blood from infected patients and blood components from infected asymptomatic blood donors is, however, concerning. This study investigated the efficacy of the amotosalen/UVA light (A/UVA) and amustaline (S-303)/glutathione (GSH) pathogen reduction technologies (PRT) to inactivate SARS-CoV-2 in plasma and platelet concentrates (PC), or red blood cells (RBC), respectively. Plasma, PC prepared in platelet additive solution (PC-PAS) or 100% plasma (PC-100), and RBC prepared in AS-1 additive solution were spiked with SARS-CoV-2 and PR treated. Infectious viral titers were determined by plaque assay and log reduction factors (LRF) were determined by comparing titers before and after treatment. PR treatment of SARS-CoV-2-contaminated blood components resulted in inactivation of the infectious virus to the limit of detection with A/UVA LRF of >3.3 for plasma, >3.2 for PC-PAS-plasma, and >3.5 for PC-plasma and S-303/GSH LRF > 4.2 for RBC. These data confirm the susceptibility of coronaviruses, including SARS-CoV-2 to A/UVA treatment. This study demonstrates the effectiveness of the S-303/GSH treatment to inactivate SARS-CoV-2, and that PRT can reduce the risk of SARS-CoV-2 TTI in all blood components. |
| first_indexed | 2024-03-10T03:12:09Z |
| format | Article |
| id | doaj.art-26a6ad0d46914ddda28aa516d89e169a |
| institution | Directory Open Access Journal |
| issn | 2076-0817 |
| language | English |
| last_indexed | 2024-03-10T03:12:09Z |
| publishDate | 2022-04-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pathogens |
| spelling | doaj.art-26a6ad0d46914ddda28aa516d89e169a2023-11-23T12:31:57ZengMDPI AGPathogens2076-08172022-04-0111552110.3390/pathogens11050521Inactivation of SARS-CoV-2 in All Blood Components Using Amotosalen/Ultraviolet A Light and Amustaline/Glutathione Pathogen Reduction TechnologiesFelicia Santa Maria0Yan-Jang S. Huang1Dana L. Vanlandingham2Peter Bringmann3Cerus Corporation, Concord, CA 94520, USADepartment of Diagnostic Medicine/Pathobiology, Biosecurity Research Institute, Kansas State University, Manhattan, KS 66506, USADepartment of Diagnostic Medicine/Pathobiology, Biosecurity Research Institute, Kansas State University, Manhattan, KS 66506, USACerus Corporation, Concord, CA 94520, USANo cases of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transfusion-transmitted infections (TTI) have been reported. The detection of viral RNA in peripheral blood from infected patients and blood components from infected asymptomatic blood donors is, however, concerning. This study investigated the efficacy of the amotosalen/UVA light (A/UVA) and amustaline (S-303)/glutathione (GSH) pathogen reduction technologies (PRT) to inactivate SARS-CoV-2 in plasma and platelet concentrates (PC), or red blood cells (RBC), respectively. Plasma, PC prepared in platelet additive solution (PC-PAS) or 100% plasma (PC-100), and RBC prepared in AS-1 additive solution were spiked with SARS-CoV-2 and PR treated. Infectious viral titers were determined by plaque assay and log reduction factors (LRF) were determined by comparing titers before and after treatment. PR treatment of SARS-CoV-2-contaminated blood components resulted in inactivation of the infectious virus to the limit of detection with A/UVA LRF of >3.3 for plasma, >3.2 for PC-PAS-plasma, and >3.5 for PC-plasma and S-303/GSH LRF > 4.2 for RBC. These data confirm the susceptibility of coronaviruses, including SARS-CoV-2 to A/UVA treatment. This study demonstrates the effectiveness of the S-303/GSH treatment to inactivate SARS-CoV-2, and that PRT can reduce the risk of SARS-CoV-2 TTI in all blood components.https://www.mdpi.com/2076-0817/11/5/521SARS-CoV-2pathogen reduction technologyamotosalenamustaline |
| spellingShingle | Felicia Santa Maria Yan-Jang S. Huang Dana L. Vanlandingham Peter Bringmann Inactivation of SARS-CoV-2 in All Blood Components Using Amotosalen/Ultraviolet A Light and Amustaline/Glutathione Pathogen Reduction Technologies Pathogens SARS-CoV-2 pathogen reduction technology amotosalen amustaline |
| title | Inactivation of SARS-CoV-2 in All Blood Components Using Amotosalen/Ultraviolet A Light and Amustaline/Glutathione Pathogen Reduction Technologies |
| title_full | Inactivation of SARS-CoV-2 in All Blood Components Using Amotosalen/Ultraviolet A Light and Amustaline/Glutathione Pathogen Reduction Technologies |
| title_fullStr | Inactivation of SARS-CoV-2 in All Blood Components Using Amotosalen/Ultraviolet A Light and Amustaline/Glutathione Pathogen Reduction Technologies |
| title_full_unstemmed | Inactivation of SARS-CoV-2 in All Blood Components Using Amotosalen/Ultraviolet A Light and Amustaline/Glutathione Pathogen Reduction Technologies |
| title_short | Inactivation of SARS-CoV-2 in All Blood Components Using Amotosalen/Ultraviolet A Light and Amustaline/Glutathione Pathogen Reduction Technologies |
| title_sort | inactivation of sars cov 2 in all blood components using amotosalen ultraviolet a light and amustaline glutathione pathogen reduction technologies |
| topic | SARS-CoV-2 pathogen reduction technology amotosalen amustaline |
| url | https://www.mdpi.com/2076-0817/11/5/521 |
| work_keys_str_mv | AT feliciasantamaria inactivationofsarscov2inallbloodcomponentsusingamotosalenultravioletalightandamustalineglutathionepathogenreductiontechnologies AT yanjangshuang inactivationofsarscov2inallbloodcomponentsusingamotosalenultravioletalightandamustalineglutathionepathogenreductiontechnologies AT danalvanlandingham inactivationofsarscov2inallbloodcomponentsusingamotosalenultravioletalightandamustalineglutathionepathogenreductiontechnologies AT peterbringmann inactivationofsarscov2inallbloodcomponentsusingamotosalenultravioletalightandamustalineglutathionepathogenreductiontechnologies |